‘.. The results of the study showed that CCX354 was well tolerated and showed a linear dose – risk profile in single-dose and multiple-dose Phase I studies in healthy volunteers. Are confident that far above those required for adequate receptor blockade. High levels of receptor coverage at the 12-hour time point were achieved after a single dose of 100 mg of CCX354. – ‘Our data and the reports of other labs now show that the importance of a high degree of CCR1 receptor coverage to achieve a therapeutic effect in inflammatory diseases such as RA,’said Thomas J. President and Chief Executive Officer of ChemoCentryx. ‘We are extremely pleased that this study demonstrated the unique ability of CCX354, selectively and sufficiently block the CCR1 receptor ssobjectives that other molecules in this class failed to achieve to date.

CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor, the recruitment of inflammatory monocytes and macrophages in the drives joints of patients with RA. By selectively blocking the CCR1 receptor is designed CCX354, Although of inflammatory cells in the joints of patients to decrease rheumatoid arthritis and inhibition of inflammation, swelling, pain and associated joint destruction while minimizing the potential for off-target effects, thus a wider therapeutic window than currently approved therapies.Showed These results demonstrate that issuing on adolescent boys moderate impulsive behavior, unlike those of in the high or low groups, towards, there were a significant increase in impulsive behavior when committed to heavy alcohol consumption in the previous year.

An interactive card allows users to consider up and download single status information and provides states on compare various measures is available here.